Advertisement

Medical Oncology

, 37:5 | Cite as

Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKCα/ERK1/2 and PI3K/Akt pathway

  • Li Zhang
  • Baofei Jiang
  • Ni Zhu
  • Mingyue Tao
  • Yali Jun
  • Xiaofei ChenEmail author
  • Qilong WangEmail author
  • Chao LuoEmail author
Original Paper
  • 93 Downloads

Abstract

Mps1/TTK plays an important role in development of many tumors. The purpose of the present study was designed to investigate the role of TTK in colon cancer. We analyzed TTK and colon cancer in the GEO database, colon cancer tissues and normal tissues were collected to verify the results by immunohistochemistry. We detected the TTK expression in the colon cancer cell lines, and overexpressed or silenced TTK expression in colon cancer cell lines. GEO database showed that the expression of TTK was higher in the colon cancer tissues than normal tissues, higher level of TTK shows unfavourable prognosis in colon patients. Furthermore, high differentiation of colon shows the lower expression of TTK. The higher expression of TTK links with the high microsatellite status. However, the expression of TTK has no significant difference among the different stages of colon cancer patients, and has no significant relationship with recurrence or relapse. Here, we also report that the differential expression of TTK in colon cancer cells alters the intrinsic negative regulation of cell proliferation and differentiation, resulting in the difference of proliferation and differentiation capacity. TTK could activate the PKCα/ERK1/2 to influence the proliferation and inactivate the PI3K/AKT pathway to inhibition the expression of MUC2 and TFF3 that related to the differentiation of colon cells. In conclusions, TTK promote the colon cancer cell proliferation via activation of PKCα/ERK1/2 and inhibit the differentiation via inactivation of PI3K/Akt pathway. TTK inhibition may be the potential therapeutic pathway for the treatment of colon cancer.

Keywords

GEO dataset Mps1/TTK Colon cancer Differentiation Prognosis PKCα/ERK1/2/PI3K/AKT pathway 

Notes

Acknowledgements

This work was supported by National Natural Science Foundation of China (Grant Nos. 81972739 and 81800149), and Natural Science Foundation of Jiangsu Province (Grant No. BK20170455). Hubei Provincial Natural Science Foundation of China (Grant No. 2018CFB173). Research Project of HuBei Provincial Department of Education (Grant No. Q20172802). Transforming Medical Research Innovative Talents Project (Grant No. YZHT201901).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Supplementary material

12032_2019_1320_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 15 kb)
12032_2019_1320_MOESM2_ESM.tif (150 kb)
Supplementary material 2 (TIFF 149 kb)
12032_2019_1320_MOESM3_ESM.tif (2.4 mb)
Supplementary material 3 (TIFF 2407 kb)
12032_2019_1320_MOESM4_ESM.tif (1 mb)
Supplementary material 4 (TIFF 1061 kb)
12032_2019_1320_MOESM5_ESM.tif (776 kb)
Supplementary material 5 (TIFF 775 kb)

References

  1. 1.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefGoogle Scholar
  2. 2.
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefGoogle Scholar
  3. 3.
    Matloff ET, Brierley KL, Chimera CM. A clinician’s guide to hereditary colon cancer. Cancer J. 2004;10(5):280–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Jemaà M, Galluzzi L, Kepp O, et al. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death Differ. 2013;20(11):1532–45.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Liu X, Winey M. The MPS1 family of protein kinases. Annu Rev Biochem. 2012;81:561–85.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Maia AR, de ManJ Boon U, et al. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Ann Oncol. 2015;26(10):2180–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Gong W, Zhang GM, Liu Y, et al. IFN-gamma withdrawal after immunotherapy potentiates B16 melanoma invasion and metastasis by intensifying tumor integrin alphavbeta3 signaling. Int J Cancer. 2008;123(3):702–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Liu D, Li L, Zhang XX, Wan DY, Xi BX, Hu Z, et al. SIX1 promotes tumor lymphangiogenesis by coordinating TGFβ signals that increase expression of VEGF-C. Cancer Res. 2014;74:5597–607.PubMedCrossRefGoogle Scholar
  9. 9.
    Weber TK, Steele G, Summerhayes IC. Differential pp60c-src activity in well and poorly differentiated human colon carcinomas and cell lines. J Clin Invest. 1992;90(3):815–21.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Zhou YH, Liao SJ, Li D, Luo J, Wei JJ, Yan B, et al. TLR4 ligand/H2O2 enhances TGF-β1 signaling to induce metastatic potential of non-invasive breast cancer cells by activating non-Smad pathways. PLoS ONE. 2013;8:e65906.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Wang Z, Liu JQ, Liu Z, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol. 2013;190(5):2415–23.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Lv D, Jia F, Hou Y, et al. Histone acetyltransferase KAT6A upregulates PI3K/AKT signaling through TRIM24 binding. Cancer Res. 2017;77(22):6190–201.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Durual S, Blanchard C, Perrot V, et al. Expression of human TFF3 in relation to growth of HT-29 cell subpopulations: involvement of PI3-K but not STAT6. Differentiation. 2015;73(1):36–44.CrossRefGoogle Scholar
  14. 14.
    Dominguez Brauer C, Thu KL, Mason JM, et al. Targeting mitosis in cancer: emerging strategies. Mol Cell. 2015;60(4):524–36.PubMedCrossRefGoogle Scholar
  15. 15.
    Martinez R, Blasina A, Hallin JF, et al. Mitotic checkpoint kinase Mps1 has a role in normal physiology which impacts clinical utility. PLoS ONE. 2015;10(9):e0138616.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Mills GB, Schmandt R, McGill M, et al. Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem. 1992;267(22):16000–6.PubMedGoogle Scholar
  17. 17.
    Iwakiri D, Podolsky DK. Keratinocyte growth factor promotes goblet cell differentiation through regulation of goblet cell silencer inhibitor. Gastroenterology. 2001;120(6):1372–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Housley RM, Morris CF, Boyle W, et al. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest. 1994;94(5):1764–77.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Taupin D, Podolsky DK. Mitogen-activated protein kinase activation regulates intestinal epithelial differentiation. Gastroenterology. 1999;116(5):1072–80.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol. 2003;4(9):721–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Ji CD, Wang YX, Xiang DF, Bian XW, et al. Kir21 interaction with Stk38 promotes invasion and metastasis of human gastric cancer by enhancing MEKK2-MEK1/2-ERK1/2 signaling. Cancer Res. 2018;78(11):3041–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Little AS, Smith PD, Cook SJ, et al. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene. 2013;32(10):1207–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Durual S, Blanchard C, Estienne M, et al. Expression of human TFF3 in relation to growth of HT-29 cell subpopulations: involvement of PI3-K but not STAT6. Differentiation. 2005;73(1):36–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Yu ZC, Huang YF, Shieh SY. Requirement for human Mps1/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation. Nucleic Acids Res. 2016;44(3):1133–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Wang X, Yu H, Xu L, et al. Dynamic autophosphorylation of mps1 kinase is required for faithful mitotic progression. PLoS ONE. 2014;9(9):e104723.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Poynter JN, Siegmund KD, Weisenberger DJ, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomark Prev. 2008;17(11):3208–15.CrossRefGoogle Scholar
  28. 28.
    Campbell PT, Jacobs ET, Ulrich CM, et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst. 2010;102(6):391–400.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Drucker A, Arnason T, Yan SR, et al. Ephrin B2 receptor and microsatellite status in lymph node-positive colon cancer survival. Transl Oncol. 2013;6(5):520–7.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Lan W, Cleveland DW, et al. A chemical tool box defines mitotic and interphase roles for Mps1 kinase. J Cell Biol. 2010;190(1):21–4.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Tannous BA, Kerami M, Van der Stoop PM, et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst. 2013;105(17):1322–31.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Slee RB, Grimes BR, Bansal R, et al. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Mol Cancer Ther. 2014;13(2):307–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Colombo R, Caldarelli M, Mennecozzi M, et al. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res. 2010;70(24):10255–64.PubMedCrossRefGoogle Scholar
  34. 34.
    Maire V, Baldeyron C, Richardson M, et al. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS ONE. 2013;8(5):e63712.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Miao R, Wu Y, Zhang H, et al. Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer. Sci Rep. 2016;6:33121.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Kaistha BP, Honstein T, Müller V, et al. Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells. Br J Cancer. 2014;111(9):1780–7.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A, et al. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. Oncotarget. 2016;7(16):22865–72.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Hudler P, Britovsek NK, Grazio SF, et al. Association between polymorphisms in segregation genes BUB1B and TTK and gastric cancer risk. Radiol Oncol. 2016;50(3):297–307.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Gouyer V, Wiede A, Buisine MP, et al. Specific secretion of gel-forming mucins and TFF peptides in HT-29 cells of mucin-secreting phenotype. Biochim Biophys Acta. 2001;1539(1–2):71–84.PubMedCrossRefGoogle Scholar
  40. 40.
    Podolsky DK, Lynch-Devaney K, Stow JL, et al. Identification of human intestinal trefoil factor Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem. 1993;268(16):6694–702.PubMedGoogle Scholar
  41. 41.
    Velcich A. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 2002;295(5560):1726–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Wang Q, Wang X, Hernandez A, et al. Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation. Gastroenterology. 2001;120(6):1381–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Central Laboratory and Huai’an Key Laboratory of Esophageal Cancer Biobank, The Affiliated Huaian No. 1 People’s HospitalNanjing Medical UniversityHuai’anChina
  2. 2.Department of Gastrointestinal Surgery, The Affiliated Huaian No. 1 People’s HospitalNanjing Medical UniversityHuaianChina
  3. 3.Department of MicrobiologyHubei University of Science and TechnologyXianningChina

Personalised recommendations